XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
 3 Months Ended
Jul. 31, 2017
Segment Reporting [Abstract]  
Summary of Segment Activity
The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three months ended July 31, 2017
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
439

 
$
4,594

 
$
—

 
$
5,033

Direct cost of services
 
(386
)
 
(2,229
)
 
—

 
(2,615
)
Sales and marketing costs
 
(86
)
 
(563
)
 
—

 
(649
)
Other operating expenses
 
—

 
(1,038
)
 
(786
)
 
(1,824
)
Stock- based compensation expense (1)
 
—

 
—

 
(564
)
 
(564
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(33
)
 
$
764

 
$
(1,350
)
 
$
(619
)
 
Three months ended July 31, 2016
 
Personalized
Oncology
Solutions
(POS)
 
Translational
Oncology
Solutions
(TOS)
 
Unallocated
Corporate
Overhead
 
Consolidated
Net revenue
 
$
511

 
$
3,159

 
$
—

 
$
3,670

Direct cost of services
 
(472
)
 
(2,005
)
 
—

 
(2,477
)
Sales and marketing costs
 
(141
)
 
(616
)
 
—

 
(757
)
Other operating expenses
 
—

 
(1,126
)
 
(704
)
 
(1,830
)
Stock- based compensation expense (1)
 
—

 
—

 
(1,129
)
 
(1,129
)
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(102
)
 
$
(588
)
 
$
(1,833
)
 
$
(2,523
)
 
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. See Note 3 for the allocation of stock compensation expense relative to the individual line items as it is reported on the Company's Consolidated Statements of Operations.